← Leaderboards
Katherine N Cahill
Brigham And Women'S Hospital
$6,985,885
Attributed
$11,528,703
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,528,703 · 4
By mechanism
U01$8,604,388 · 1
R01$1,491,931 · 1
K23$951,135 · 1
R21$481,249 · 1
Top collaborators
- Gordon R. Bernard6 shared
- Dawn C Newcomb1 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Joshua A Boyce$54,050,346
- Nora Amanda Barrett$12,519,597
- Tanya Maria Laidlaw$5,208,119
- Elliot Israel$35,880,602
- Lora Bankova$3,136,705
Others in their field
Top investigators on “Asthma”
- James E. Gern · University Of Wisconsin-Madison$159,588,264
- William W. Busse · University Of Wisconsin Madison$104,093,792
- Scott T Weiss · University Of California, San Diego$98,211,117
- David T Mauger · Pennsylvania State Univ Hershey Med Ctr$79,309,576
- Fernando D Martinez · University Of Arizona$66,357,737
- Wanda Phipatanakul · Boston Children'S Hospital$50,505,446
Research focus
AsthmaInflammationAsthmatic PatientExhalationMediatingSymptomsAdultRespiratory SystemQuality Of LifeInsightTissuesEosinophilAsthma ExacerbationAllergensGlp-I ReceptorGlucagon-Like Peptide 1Airway InflammationAgonistComorbidityClinical DataFda ApprovedObesityPathway InteractionsSampling
Grant awards (15)
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma$1,583,667
U01 · FY2025 · AI · contact PI
GLP-1R agonist immune targets in lean and obesity-associated asthma$745,797
R01 · FY2025 · AI · contact PI
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma$686,053
U01 · FY2025 · AI · contact PI
Mechanisms by which Glp-1 and Gip receptor signaling enhance airway epithelial barrier function$481,249
R21 · FY2025 · AI · contact PI
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma$1,583,667
U01 · FY2024 · AI · contact PI
GLP-1R agonist immune targets in lean and obesity-associated asthma$746,134
R01 · FY2024 · AI · contact PI
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma$1,583,667
U01 · FY2023 · AI · contact PI
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma$1,583,667
U01 · FY2022 · AI · contact PI
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma$1,583,667
U01 · FY2021 · AI · contact PI
THE ROLE OF PROSTAGLANDIN D2 IN THE RESPIRATORY SYMPTOMS OF ASPIRIN EXACERBATED RESPIRATORY DISEASE$185,415
K23 · FY2019 · AI · contact PI
THE ROLE OF PROSTAGLANDIN D2 IN THE RESPIRATORY SYMPTOMS OF ASPIRIN EXACERBATED RESPIRATORY DISEASE$102,718
K23 · FY2018 · AI · contact PI
The Role of Prostaglandin D2 in the Respiratory Symptoms of Aspirin Exacerbated Respiratory Disease$94,922
K23 · FY2018 · AI · contact PI
The Role of Prostaglandin D2 in the Respiratory Symptoms of Aspirin Exacerbated Respiratory Disease$197,640
K23 · FY2017 · AI · contact PI
The Role of Prostaglandin D2 in the Respiratory Symptoms of Aspirin Exacerbated Respiratory Disease$185,220
K23 · FY2016 · AI · contact PI
The Role of Prostaglandin D2 in the Respiratory Symptoms of Aspirin Exacerbated Respiratory Disease$185,220
K23 · FY2015 · AI · contact PI